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The prion strain-speciﬁc mechanism by which normal prion protein is converted to abnormal prion
protein remains largely unknown. This study found that insect juvenile hormone III reduced abnormal
prion protein levels only in cells infected with the RML prion. We conducted a structure–activity analysis
using juvenile hormone III biosynthetic intermediates in the isoprenoid pathway. Both farnesol and
geranylgeraniol, the most potent inhibitors of abnormal prion protein formation, behaved in an RML
prion-dependent fashion. Neither of them modiﬁed cellular and cell surface prion protein levels. Events
downstream of this pathway include cholesterol biosynthesis and protein prenylation. However, neither
of these isoprenoid compounds modiﬁed lipid raft microdomains and cellular cholesterol levels and
neither affected the representative prenylated protein expression levels of prenylation pathways.
Therefore, these isoprenoid compounds are a new class of prion strain-dependent antiprion compounds.
They are useful for exploring strain-speciﬁc prion biology.
& 2015 Elsevier Inc. All rights reserved.Introduction
Prion diseases are progressive, fatal neurodegenerative ill-
nesses. They include Creutzfeldt–Jakob disease in humans and
scrapie, bovine spongiform encephalopathy, and chronic wasting
disease in animals. These diseases are characterized by the accu-
mulation of abnormal prion protein (abnormal PrP), the main
component of the pathogen, and it is conformationally trans-
formed from the normal prion protein (PrPc) (Prusiner, 1998).
Abnormal PrP forms an insoluble protein polymer with a protease-
resistant core (PrPres). The conversion of PrPc to abnormal PrP and
the turnover of abnormal PrP in prion-infected cells are key events
in prion disease, but they remain largely enigmatic.
As remedies for these diseases, dozens of compounds or sub-
stances reportedly either inhibit prion formation in prion-infected
cultured cells or prolong incubation periods in prion-infected
animals (Sim, 2012; Teruya and Doh-ura, 2013; Trevitt andllular PrP; PrPres, protease-
OH, farnesol; GGOH,
ry, Tohoku University Gradu-
, Sendai 980-8575, Japan.
h-ura).Collinge, 2006). Some are known to be effective in a prion strain-
dependent fashion (Berry et al., 2013; Ishikawa et al., 2004, 2006;
Kawasaki et al., 2007), but the mechanism underlying prion strain-
dependent efﬁcacy remains to be determined. A few antiprion
compounds have been used in clinical trials against human prion
diseases, but meaningfully beneﬁcial effects in patients have never
been reported (Collinge et al., 2009; Geschwind et al., 2013; Haïk
et al., 2014; Otto et al., 2004; Tsuboi et al., 2009).
To obtain a starting point for the development of remedies and
to elucidate the enigmatic PrP conversion mechanism, we have
searched for compounds or substances that modify abnormal PrP
formation in prion-infected cells. In earlier studies (Kocisko et al.,
2003; Korth et al., 2001), an extensive array of medicinal drugs
and biological substances were screened for antiprion activity. We
speciﬁcally examined untouched materials from natural products.
Then we reported antiprion substances extracted from natural
products such as fucoidan (Doh-Ura et al., 2007) and protein-
bound polysaccharide K (Hamanaka et al., 2011). The insect is a yet
under-cultivated natural resource that exists abundantly world-
wide in terms of both number and variety. It might be possible to
discover new insect-derived substances that are useful either for
probing the PrP conversion mechanism or for developing ther-
apeutic and prophylactic treatments for the illness. In fact, antic-
ancer compounds and antivirus compounds have been found in
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et al., 2011; Slocinska et al., 2008).
For this study, we screened insect-derived substances, such as
hormones and biological peptides, using prion-infected cells.
Results showed that juvenile hormone III (JH-III) inhibited abnor-
mal PrP formation in cells infected with the RML prion. JH-III is
classiﬁed as an isoprenoid compound having a farnesane back-
bone. Because no reports have described the antiprion activity of
isoprenoid compounds, we performed a structure–activity analysis
of isoprenoid compounds and examined their antiprion mechan-
ism in prion-infected cells. The ﬁndings indicate that the antiprion
activities of isoprenoid compounds are mediated neither through
the modiﬁcation of PrPc and lipid rafts, nor through the prenyla-
tion of proteins. The results of this study suggest that isoprenoidFig. 1. Antiprion activities of insect-derived substances. (A) Immunoblotting of abnormal
(ScN2a, N167, F3) treated with insect-derived substances. Lanes 1 and 10 correspond to th
III (JH-III), methoprene, ponasterone A, α-ecdysone, 20-hydroxyecdysone, allatotropin,
allatostatin A, corazonin, drosocin, cecropin A, proctolin, and methoprene acid. Cells were
are shown as controls for the integrity of samples used for PrPres detection. Molecular
normal prion protein (PrPc) in uninfected cells (N2a) treated with insect-derived substa
cells treated with the indicated doses of JH-III. (D) Isoprenoid biosynthesis pathway.compounds are a new type of probe for elucidating prion strain-
dependent abnormal PrP formation.Results
Antiprion activities of insect-derived substances
Using persistently prion-infected cells, we examined whether
insect-derived substances have antiprion activity or not. Sixteen
substances, including hormones and their analogues as well as
biological peptides, were tested in three distinct prion strain-
infected neuroblastoma cell lines: N2a cells infected with RML
prion (ScN2a cells), N2a cells infected with 22 L prion (N167 cells),protease-resistant prion protein (PrPres) in three distinct prion strain-infected cells
e vehicle control. Lanes 2–9 and 11–19 respectively correspond to juvenile hormone
allatostatin A, muristerone A, adipokinetic hormone G, leucokinin I, leucokinin III,
treated for three days with 7.5-μg/mL insect-derived substances. Signals for β-actin
size markers on the right denote sizes in kilodalton (kDa). (B) Immunoblotting of
nces. Cells were treated as described in (A). (C) Immunoblotting of PrPres in ScN2a
Table 1
Chemical structure and antiprion activity of isoprenoid compounds.
Compound Chemical structure EC50 (mM) TC25 (mM) TC25/EC50
Juvenile hormone-III (JH-III) 9.7 41.8 4.3
Methoprene acid –*1 n.d.
Methoprene –*1 n.d.
β-β-Dimethyl-allylalcohol (DMAOH) –*2 n.d.
Geraniol (GOH) -*2 n.d.
Geranyl acetone –*1 n.d.
Farnesol (FOH) 3.0 57.1 19.0
Farnesyl pyrophosphate (FPP) 6.3 415*3 42.4
Farnesyl acetone 6.6 45.6 6.9
Farnesyl chloride 17.0 n.d.
Farnesyl bromide –*2 n.d.
Farnesyl acetate 9.7 460*3 46.2
Geranylgeraniol (GGOH) 0.9 31.2 34.7
Geranylgeranyl pyrophosphate (GGPP) 9.0 415*3 41.7
Geranylgeranyl acetone (GGA) 7.5 415*3 42
GGOH analogue 23.2 n.d.
Squalene –*2 n.d.
β-Carotene 430*2 n.d.
EC50, 50% effective concentration for inhibiting abnormal prion protein formation; TC25, 25% cytotoxic concentration; n.d., not determined; *1, tested up to 15 mM; *2, tested
up to 30 mM; *3, concentrations exceeding the indicated value could not be evaluated because of vehicle toxicity.
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infected cells were incubated with the samples at a dose of
7.5 μg/mL for three days. Then, PrPres levels were assayed by
immunoblotting.
Results revealed that only JH-III reduced PrPres levels. This
effect was observed in ScN2a cells, but not in N167 cells or F3 cells
(Fig. 1A, lane 2). Moreover, JH-III did not modify PrPc levels in
uninfected N2a cells (Fig. 1B, lane 2). In contrast, JH analogues such
as methoprene and methoprene acid (Fig. 1A, lanes 3 and 19,
respectively) were ineffective at a dose of 7.5 μg/mL, although the
50% effective concentration value (EC50) of JH-III was 9.7 μM
(3.0 μg/mL) (Fig. 1C). As shown in Table 1, JH-III has isoprene units
in its chemical structure, whereas neither methoprene nor meth-
oprene acid has an isoprene unit. Therefore, the data suggest that
isoprene units are responsible for the antiprion activity of JH-III in
ScN2a cells.
Antiprion activities of JH-III biosynthesis intermediates and related
compounds
Actually, JH-III is an isoprenoid compound synthesized in insect
cells from FOH, which comes from the isoprenoid pathway
(Fig. 1D). The isoprenoid pathway, sited downstream of the
mevalonate pathway, is also present in mammals. It is enrolled ineither the biosynthesis of cholesterol and steroids or the pre-
nylation of factors such as the small G proteins. Therefore, we
investigated whether other isoprenoid compounds reduce the
PrPres levels in ScN2a cells (Table 1).
The 5-carbon isoprenoid β,β-dimethyl-allylalcohol (DMAOH)
was ineffective at doses for which cell damage was not observed.
Similarly, 10-carbon isoprenoid compounds, including geraniol
(GOH) and geranyl acetone, were ineffective at non-toxic doses.
FOH was the most potent of the 15-carbon isoprenoid compounds
at reducing PrPres levels. Its EC50 was 3.0 μM. Farnesyl pyropho-
sphate (FPP) and farnesyl acetone were also potent: their respec-
tive EC50s were 6.3 μM and 6.6 μM. Farnesyl compounds in which
the hydroxyl group in FOH is replaced with a halide were much
less potent or impotent. The chloride showed EC50 of 17.0 μM. The
bromide was ineffective at non-toxic doses. Farnesyl acetate was
also effective, with EC50 of 9.7 μM. Among the 20-carbon iso-
prenoid compounds, GGOH was the most potent, with an excellent
EC50 (0.9 μM). Geranylgeranyl diphosphate (GGPP) and ger-
anylgeranyl acetone (GGA) were also potent, with EC50s of 9.0 μM
and 7.5 μM, respectively. An analogue of GGOH was less effective,
with EC50 of 23.2 μM. Isoprenoid compounds having carbon chains
longer than 20 carbons had no potency or much less potency. The
30-carbon isoprenoid squalene was ineffective at non-toxic doses
and 40-carbon β-carotene showed an EC50430 μM. These
Fig. 2. Effects of isoprenoids on PrP expression levels. (A) Immunoblotting of PrPres in three prion-infected cell lines treated with farnesol (FOH) or geranylgeraniol (CGOH).
(B) Immunoblotting of PrPc in N2a cells treated with FOH or GGOH. (C) Flow cytometry of cell surface PrPc in N2a cells treated with isoprenoid compounds or the vehicle
control. FOH and GGOH were used respectively at doses of 10 μM and 4.4 μM. Blue and black lines respectively represent isoprenoid-treated cells and vehicle-treated cells.
The broken line peaks on the left show their respective isotype controls. (D) Immunoblotting of autophagosomal membrane-speciﬁc form of microtubule-associated protein
light chain 3 (LC3-II) in ScN2a cells treated with FOH or GGOH. Positive controls for enhanced autophagosome formation were from ScN2a cells treated with 100 mM
trehalose. (E) Immunoblotting of PrPres or PrPc from cell lysates directly incubated with isoprenoid compounds. Cell lysates of ScN2a cells or N2a cells were incubated with
the indicated doses of FOH or GGOH for 1 h at 37 °C; subsequently PrPres or PrPc was analyzed. (F) Immunoblotting of 70-kDa heat shock protein (HSP70) or 78-kDa glucose-
regulated protein (GRP78) in ScN2a cells treated with geranylgeranyl acetone (GGA), FOH, or GGOH. Signals for PrPres and β-actin are also shown for comparison.
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are 15-carbon or 20-carbon isoprenoids with an α-terminal
hydroxyl group. The data indicate that two compounds FOH and
GGOH are the most excellent among tested compounds from the
viewpoint not only of the EC50 value but also the safety window
represented by the ratio of TC25 versus EC50.
Effects of isoprenoid compounds on PrPc and other related factors
The two isoprenoid compounds, FOH and GGOH, were ana-
lyzed further as representatives. These compounds showed anti-
prion activities in a prion-strain dependent fashion similar to that
of JH-III (Fig. 2A). The compounds did not modify PrPc levels
(Fig. 2B) or the cell surface PrPc levels in N2a cells (Fig. 2C), sug-
gesting that the compounds exert their antiprion activities with-
out modifying PrPc turnover or metabolism.
Autophagy has been reported to regulate abnormal PrP clear-
ance (Heiseke et al., 2010). Therefore, we examined whether
autophagosome formation is enhanced in ScN2a cells treated with
the isoprenoids. Results showed that these compounds did not
modify the levels of the autophagosomal membrane-speciﬁc
phosphatidylethanolamine-conjugated form of LC3 (LC3-II) in the
cells (Fig. 2D), indicating the compounds neither enhanced
autophagosome synthesis nor reduced autophagosome turnover.
Compounds such as tetracyclines (Tagliavini et al., 2000) and
polycationic compounds (Supattapone et al., 2009) reportedlyFig. 3. Mechanism of isoprenoid compounds. (A) Cellular cholesterol levels in ScN2a cel
treated for three days with GGOH at a dose of 4.4 μM or other compounds at a dose
experiments (*, Po0.05; **, Po0.01). Immunoblot data for PrPres and β-actin are also sh
raft in N2a cells or ScN2a cells treated with isoprenoid compounds or the vehicle control.
lines respectively represent isoprenoid-treated cells and vehicle-treated cells. Broken line
Ras, Rap1A/B, and Rab7 in the detergent-rich fractions or aqueous fractions from ScN2a c
used respectively at doses of 10 μM and 4.4 μM. Signals for unprenylated Rap1A and β-ac
are denoted by * and **. Molecular size markers on the right show sizes in kDa.convert abnormal PrP molecules to less protease-resistant PrP
molecules when cell lysates containing abnormal PrP molecules
are incubated with these compounds. Therefore, we tested whe-
ther FOH and GGOH modify the protease sensitivity of abnormal
PrP molecules. Results showed that the isoprenoid compounds did
not change the protease sensitivity of isoprenoid-incubated
abnormal PrP molecules and did not modify the stability of PrPc
molecules (Fig. 2E).
GGA, which is used as an antiulcer medicine in clinical settings,
protects the stomach from mucosal damage by inducing HSP70
expression (Hirakawa et al., 1996). Conversely, GGA at high con-
centrations reportedly induces GRP78 expression through endo-
plasmic reticulum stress, even in the absence of HSP70 induction
(Endo et al., 2007). Therefore, we analyzed the expression levels of
HSP70 and GRP78 in ScN2a cells treated with the isoprenoid
compounds. Results showed that the levels of HSP70 and GRP78
were not modiﬁed by these compounds in ScN2a cells, and that
HSP70 and GRP78 levels were not correlated with the antiprion
activities of the compounds (Fig. 2F).
Effects of isoprenoid compounds on cellular cholesterol and protein
prenylation
Cholesterol-lowering HMG-CoA reductase inhibitors such as
lovastatin reportedly inhibit abnormal PrP formation by perturb-
ing cholesterol synthesis and thereby destabilizing membranels treated with isoprenoid compounds, lovastatin, or the vehicle control. Cells were
of 10 μM. Data show averages and standard deviations of triplicate independent
own for comparison. (B) Flow cytometry of cell surface cholera toxin B-labeled lipid
FOH and GGOH were used respectively at doses of 10 μM and 4.4 μM. Blue and black
peaks on the left show their respective isotype IgG controls. (C) Immunoblotting of
ells treated with isoprenoid compounds or the vehicle control. FOH and GGOH were
tin are shown as controls for the integrity of the fractionations. Non-speciﬁc signals
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et al., 1995). Therefore, we examined whether a cholesterol-low-
ering mechanism is involved in the antiprion action of the iso-
prenoid compounds. No correlation was found between cellular
cholesterol levels and antiprion activities (Fig. 3A). Neither FOH
nor GGOH modiﬁed the cellular cholesterol levels of ScN2a cells.
Another line of evidence for the cholesterol-independent
mechanism of antiprion action was obtained through observation
of the lipid raft microdomains of the cell membrane. These lipid
raft microdomains are possible sites of PrP conversion or interac-
tion between PrPc and abnormal PrP. Cholera toxin B-binding lipid
raft levels of N2a cells and ScN2a cells were not modiﬁed by
treatment with FOH or GGOH (Fig. 3B).
Finally, because isoprenoid compounds are also involved in the
prenylation of proteins, we examined whether the prenylation of
proteins is related to the antiprion activities of isoprenoid com-
pounds or not. We investigated all three types of protein pre-
nylation (Fig. 1D) in ScN2a cells by assaying the unprenylated and
prenylated levels of such representative proteins as Ras, Rap1A/B,
and Rab7, which are respectively subject to farnesyltransferase-
mediated prenylation, geranylgeranyltransferase type I-mediated
prenylation, and geranylgeranyltransferase type II-mediated pre-
nylation. Results demonstrated that the presence of FOH or GGOH
in the medium did not change the proportions of unprenylated
protein levels (in the aqueous fractions), and that the prenylated
protein levels (in the detergent-rich fractions) of Ras, Rap1A/B, and
Rab7 were comparable to those of the control (Fig. 3C). These
results suggest that the prenylation of proteins is not involved in
the antiprion activities of isoprenoid compounds in ScN2a cells.Discussion
This study demonstrated that isoprenoid compounds inhibited
abnormal PrP formation in prion-infected cells. Representative
compounds JH-III, FOH, and GGOH showed dose-dependent, prion
strain-dependent antiprion activity. Structure–activity studies
revealed that the most potent antiprion compounds were 15-car-
bon or 20-carbon isoprenoids with an α-terminal hydroxyl group.
Although many compounds or biological materials have previously
been reported to inhibit the abnormal PrP formation in prion-
infected cells, isoprenoid compounds have never been reported.
They are therefore a new class of antiprion compounds.
The isoprenoid pathway is sited downstream of the mevalonate
pathway. Isoprenoids are intermediates in cholesterol biosynth-
esis. Numerous reports describe that cholesterol modulators have
antiprion activity. These compounds reportedly disturb membrane
lipid raft microdomains, a possible site of PrP conversion or
interaction between PrPc and abnormal PrP (Bate et al., 2004,
2010; Gilch et al., 2006, 2009; Klingenstein et al., 2006; Kumar
et al., 2008; Lewis and Hooper, 2011; Marella et al., 2002; Pani
et al., 2007; Prior et al., 2007; Rouvinski et al., 2014; Taraboulos
et al., 1995). In addition, cholesterol metabolism is reportedly
impaired in prion-infected cells, and cellular cholesterol levels are
connected reciprocally with abnormal PrP levels (Cui et al., 2014).
In the present study, however, two representative antiprion
compounds, FOH and GGOH, did not modify cellular cholesterol
levels or membrane lipid raft microdomain levels. This result
strongly suggests that these isoprenoid compounds exert their
antiprion activity in a cholesterol-independent manner.
Results of the present study also suggest that protein prenyla-
tion is unlikely to be involved in the mechanism of antiprion
action of the isoprenoid compounds. The proportions of either the
unprenylated protein levels in the aqueous fractions or the pre-
nylated protein levels in the detergent-rich fractions were not
changed by isoprenoid treatment. Prenylation, in which C-terminalcysteine residues are covalently modiﬁed with farnesyl or ger-
anylgeranyl isoprenoid groups, is a mechanism through which
cytoplasmic proteins associate with the membrane. Protein pre-
nylation is mediated by three protein prenyltransferase enzymes:
farnesyltransferase, for farnesylation of proteins such as Ras and
nuclear lamins; geranylgeranyltransferase type I, for geranylger-
anylation of proteins such as Rho, Rac, and Rap1; and ger-
anylgeranyltransferase type II, for geranylgeranylation of Rab.
Among these, prenylated Rab proteins are known to regulate
membrane trafﬁcking in vesicle formation, organelle movement,
and membrane tethering/fusion. Membrane trafﬁcking along the
endocytic-recycling and the endo-lysosomal pathways is report-
edly involved in abnormal PrP formation or degradation (Beranger
et al., 2002; Borchelt et al., 1992; Caughey and Raymond, 1991;
Marijanovic et al., 2009; Taraboulos et al., 1992; Yamasaki et al.,
2014). Therefore, it was natural to infer that isoprenoid supple-
mentation to prion-infected cells would modify protein prenyla-
tion levels and thereby cause a reduction in abnormal PrP levels.
However, this presumption turned out not to be true because no
changes in protein prenylation levels were observed in the present
study.
In addition to the non-involvement of cholesterol biosynthesis
and protein prenylation, the isoprenoid compounds did not
inﬂuence any relevant factors such as total cellular and cell surface
PrPc levels, autophagosome levels, or heat shock protein levels. At
the same time, they were active in a prion strain-dependent
manner. Considering all these together, the results suggest that the
compounds reduce abnormal PrP levels by directly modifying
abnormal PrP formation or turnover. We have experienced similar
results in prion-infected cells with amyloidophilic compounds
such as compound B, BSB, and styrylbenzoazole derivatives, all of
which also showed prion strain-dependent efﬁcacy in vivo (Ishi-
kawa et al., 2004, 2006; Kawasaki et al., 2007; Teruya and Doh-ura,
2013). We have speculated that the prion strain-dependent efﬁ-
cacy of these compounds is attributable to strain-speciﬁc struc-
ture, biosynthesis, or turnover of abnormal PrP molecules. How-
ever, to date, none of these mechanisms of prion strain-depen-
dency has been veriﬁed. The present ﬁndings of a new class of
antiprion compounds might provide clues to elucidate the
mechanisms of strain-dependent antiprion activity.
Finally, the ﬁndings of this study suggest that the mechanisms
of abnormal PrP formation in prion-infected cells are not the same
for different prion strains. The ﬁndings also suggest that iso-
prenoid compounds are a new tool for resolving the enigma of
prion strain-dependent prion formation. The most excellent iso-
prenoid compound GGOH in the present study has an EC50 value
comparable to 2-aminothiazole compounds (IND-24 and IND-81),
which are the most effective antiprion compounds reported
recently in RML prion-infected N2a cells and animals (Berry et al.,
2013; Silber et al., 2013). This similarity implies that the isoprenoid
compound can be anticipated for use as a lead compound and as a
source of clues for discovering a new target for remedy develop-
ment, although the in vivo efﬁcacy of the compound remains to be
evaluated.Materials and methods
Compounds
We obtained all insect-derived substances and their analogues,
which include JH-III, methoprene acid, methoprene, corazonin,
proctolin, drosocin, cecropin A, α-ecdysone, 20-hydroxyecdysone,
ponasterone A, muristerone A, adipokinetic hormone G, leucokinin
I, leucokinin III, allatotropin, and allatostatin A from commercial
sources. Hormones and peptides were dissolved respectively in
T. Hamanaka et al. / Virology 486 (2015) 63–70 69100% ethanol and distilled water. The isoprenoid compounds and
their related compounds obtained for this study (Sigma-Aldrich)
were dissolved in 100% ethanol.Analysis of PrP and other factors
We used mouse neuroblastoma N2a cells as well as three types
of distinct prion strain-infected N2a-derived cells: ScN2a cells
infected with the RML prion, N167 cells infected with the 22L
prion, and F3 cells infected with the Fukuoka-1 prion. Cells were
treated for three days with test materials as described previously
(Doh-Ura et al., 2000; Ishikawa et al., 2006; Kawasaki et al., 2007).
Cell lysates were prepared using lysis buffer (0.5% sodium deox-
ycholate, 0.5% Nonidet P-40, PBS, pH 7.4). The amounts of PrPres,
PrPc, β-actin, autophagosomal microtubule-associated protein
light chain 3 (LC3), 70-kDa heat shock protein (HSP70), and 78-
kDa glucose-regulated protein (GRP78) in the cell lysates were
analyzed using immunoblotting with each speciﬁc antibody, as
described in a previous report (Nishizawa et al., 2014), or with
anti-HSP70 (1:10,000, BD Transduction Labs) or anti-GRP78
(1:5000, BD Transduction Labs). For the analysis of cell-surface
PrPc levels in N2a cells and lipid raft microdomain levels in N2a
cells and ScN2a cells, ﬂow cytometry was performed using anti-
PrP monoclonal antibody and ﬂuorescence-conjugated cholera
toxin B, respectively, as described in a previous report (Nishizawa
et al., 2014). Cell viability was analyzed (Cell Counting Kit-8;
Dojindo Molecular Technologies) to monitor the cytotoxicity of
compounds. For each sample, the 50% effective concentration
value (EC50) for inhibiting PrPres formation, the 25% cytotoxic
concentration value (TC25), and other statistical data were
obtained from results of triplicate analyses.
Analysis of cholesterol and protein prenylation
The cholesterol contents of cells were analyzed using a cho-
lesterol assay kit (Amplex Red; Molecular Probes Inc.) according to
the manufacturer's instructions. Proportions of cytosolic unpre-
nylated and membrane-bound prenylated proteins were assayed
as described previously (Coxon et al., 2005), using Triton X-114
fractionation to separate the prenylated and unprenylated forms of
proteins in whole cell lysates. ScN2a cells treated with farnesol
(FOH) or geranylgeraniol (CGOH) for 24 h or 72 h were washed in
PBS, then lysed in Triton X-114 buffer (20 mM Tris, 150 mM NaCl,
pH 7.5, 1% Triton X-114). Lysates were clariﬁed by centrifugation at
13,000 g for 10 min. Then they were incubated at 37° for 10 min.
Following centrifugation at 20,000 g for 5 min, the aqueous
phases (aqueous fractions) were removed to fresh tubes. Buffer
without Triton X-114 was added to the detergent-rich phases
(detergent-rich fractions) to equalize the volume with the aqueous
phases. Then an aliquot of each phase was electrophoresed on a
15% polyacrylamide gel. These were then analyzed by immuno-
blotting with antibodies against Ras (1:2000, GeneTex), Rap1A/B
(1:50, Santa Cruz Biotechnology Inc.), Rab7 (1:1000, Cell Signaling
Technology), unprenylated Rap1A (1:100, Santa Cruz Biotechnol-
ogy Inc.), or β-actin.Acknowledgments
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